On this page
Langer-Giedion syndrome
Also known as trichorhinophalangeal syndrome type II · 8q24.11-q24.13 deletion · TRPS II
Langer-Giedion syndrome, also called TRPS II, is a genetic condition that affects bone and connective tissues, as well as intellectual development. It is caused by a small missing piece of genetic material (a microdeletion) on chromosome 8, usually occurring sporadically.
Available at Jeen Health
Clinical tests that include this
Overview
Langer-Giedion syndrome (LGS), also known as trichorhinophalangeal syndrome type II (TRPS II), is a very rare genetic condition. It is characterised by a combination of distinctive physical features, including specific skeletal abnormalities and intellectual disability. Affected individuals often have sparse hair, a bulbous nose, and prominent ears, along with multiple bone growths (exostoses) [PMID:33679878]. The condition is a contiguous gene deletion syndrome, meaning it results from the loss of several neighbouring genes on chromosome 8. While fewer than 100 cases have been reported worldwide, the full spectrum of features can vary among affected individuals.
This syndrome is considered a microdeletion disorder, meaning a small segment of genetic material is missing. This missing segment typically includes two specific genes, TRPS1 and EXT1, and it is the loss of these genes that leads to the diverse features observed in LGS [PMID:19452425]. The condition is usually not inherited from a parent but arises spontaneously (sporadically) during the formation of reproductive cells or early embryonic development. Management focuses on addressing the specific symptoms and needs of each individual.
Symptoms & clinical features
Individuals with Langer-Giedion syndrome present with a range of characteristic symptoms affecting various body systems. Skeletal abnormalities are common and include multiple cartilaginous exostoses, which are benign bone growths that can occur near joints. These exostoses may lead to pain, limited joint movement, or nerve compression [PMID:33679878]. Short stature is also frequently observed.
Distinctive facial features are a hallmark of LGS. These often include sparse hair, particularly on the scalp, a bulbous or pear-shaped nose, a long philtrum (the groove between the base of the nose and the upper lip), and prominent ears. The fingers and toes may also appear shortened or abnormal. Many individuals with LGS experience mild-to-moderate intellectual disability, which can affect learning and development. Other potential symptoms may include loose skin, particularly in childhood, recurrent ear infections, and dental anomalies. The severity and combination of these symptoms can differ from person to person.
Video: Genetics 101
Affected organs
Langer-Giedion syndrome primarily affects the skeletal system, skin, and neurological development. The skeletal system is notably impacted by the formation of multiple osteochondromas, also known as exostoses. These are benign bone tumours that grow outwards from the surface of bones, often near growth plates, and can lead to pain, restricted movement, and sometimes nerve or blood vessel compression [PMID:33679878]. Bones of the hands and feet may also be affected, leading to short digits or other structural changes.
Skin and hair are also commonly affected; individuals often have sparse, fine hair and sometimes loose or excess skin. The unique facial features arise from the development of underlying bone and cartilage structures in the face. Neurological involvement typically manifests as developmental delay and mild-to-moderate intellectual disability, affecting brain function. While specific organ failure is not characteristic of LGS, the widespread nature of connective tissue and skeletal issues means many body parts can be indirectly affected by the exostoses and developmental differences.
Risks & severity
Langer-Giedion syndrome is considered a rare condition, with fewer than 100 cases reported globally, meaning exact prevalence figures are not well established. The severity of LGS can vary among affected individuals, even with the same underlying genetic deletion. The skeletal abnormalities, particularly the multiple exostoses, typically develop during childhood and can increase in size over time. These growths carry a small risk of malignant transformation into chondrosarcoma in adulthood, similar to hereditary multiple exostoses, though this risk is generally low [PMID:33679878].
Intellectual disability associated with LGS is usually in the mild-to-moderate range, though some individuals may experience more significant learning difficulties. Regular monitoring for exostosis-related complications, such as pain or restricted movement, is important. The long-term outlook for individuals with LGS depends on the specific constellation and severity of their symptoms, with ongoing medical and developmental support generally required throughout life.
Genetic causes
Langer-Giedion syndrome is caused by a microdeletion on the long arm of chromosome 8, specifically in the 8q24.11-q24.13 region. This deletion typically involves two crucial genes: TRPS1 and EXT1. The deletion of these neighbouring genes, rather than a change in a single gene, is responsible for the diverse clinical features of the syndrome.
The EXT1 gene provides instructions for making a protein called exostosin glycosyltransferase 1. This protein is involved in the formation of heparan sulphate proteoglycans, which are important molecules on cell surfaces and in the extracellular matrix. These molecules play a role in cell growth, differentiation, and development, particularly of cartilage and bone. A functional EXT1 gene is critical for normal cartilage and bone development; its loss contributes to the formation of multiple exostoses observed in LGS [PMID:19452425]. The TRPS1 gene is also deleted in LGS, and its loss is associated with the distinctive facial features and other skeletal abnormalities seen in the syndrome. The combined loss of these genes results in the characteristic phenotype of Langer-Giedion syndrome.
- EXT1 exostosin glycosyltransferase 1
Inheritance pattern
Langer-Giedion syndrome is typically inherited in a sporadic pattern. This means that the genetic change - the microdeletion on chromosome 8 - usually occurs spontaneously and is not inherited from either parent. In such sporadic cases, the deletion happens either during the formation of the egg or sperm cell, or very early in embryonic development, and neither parent carries the deletion in their somatic cells.
Because the condition is generally sporadic, affected individuals are often the first in their family to have the syndrome. The risk of parents having another child with Langer-Giedion syndrome is very low in these cases. However, if a parent were found to have a mosaic deletion (meaning the deletion is present in some, but not all, of their cells), or a balanced chromosomal rearrangement involving this region, the inheritance pattern and recurrence risk would be different. Genetic counselling is important for families to understand the specific inheritance pattern and implications for future pregnancies.
Diagnosis & testing
Diagnosis of Langer-Giedion syndrome is often first suspected based on the presence of characteristic clinical features, including distinctive facial appearance, intellectual disability, and multiple cartilaginous exostoses. A definitive diagnosis is confirmed through genetic testing that can identify the specific microdeletion on chromosome 8 [PMID:33679878].
Genetic testing methods such as chromosomal microarray (CMA) or fluorescence in situ hybridisation (FISH) can detect the deletion of the 8q24.11-q24.13 region, which typically encompasses the TRPS1 and EXT1 genes. In the UK, if LGS is suspected, a clinical genetics service referral would typically be made via a GP or paediatrician. Genetic testing for intellectual disability and related syndromes is covered under the NHS Genomic Medicine Service, often utilising the R-code R11 (Intellectual disability), which includes detection of microdeletions. Genetic counsellors can help families understand the testing process and interpret the results.
Management & lifestyle
Management of Langer-Giedion syndrome focuses on addressing the specific symptoms and complications that arise. There is no cure for the underlying genetic cause, so care is largely supportive and multidisciplinary. Regular monitoring for the development and progression of osteochondromas (exostoses) is crucial. These bone growths may require surgical removal if they cause pain, restrict joint movement, or compress nerves or blood vessels. Orthopaedic specialists are typically involved in managing these skeletal issues.
Developmental support and educational interventions are important for individuals experiencing intellectual disability. This may include special educational needs provision, speech and language therapy, occupational therapy, and physiotherapy. Regular follow-up with paediatricians, clinical geneticists, and other specialists as needed is part of comprehensive care. Genetic counsellors can provide ongoing support and information to families. As the condition is rare, care pathways are individualised, guided by the specific needs of the patient within the NHS framework.
UK care pathway
In the UK, individuals suspected of having Langer-Giedion syndrome would typically enter the NHS Genomic Medicine Service pathway. Initial referral often comes from a GP or paediatrician to a regional Clinical Genetics service. Here, a clinical geneticist would assess the patient and may recommend genetic testing, such as a chromosomal microarray, to confirm a diagnosis. This testing would generally fall under NHS Genomic Medicine Service R-codes, such as R11 for Intellectual Disability. Following diagnosis, individuals and their families will have access to genetic counselling to understand the condition, its inheritance, and implications. Ongoing care usually involves a multidisciplinary team to manage the various symptoms and needs.
Frequently asked questions
Is Langer-Giedion syndrome inherited?
Langer-Giedion syndrome is usually not inherited. In most cases, the genetic change (a microdeletion) occurs spontaneously during the formation of reproductive cells or early in development, making it a sporadic condition. The risk of parents having another child with the syndrome is generally very low.
What are exostoses, and how are they managed?
Exostoses, also called osteochondromas, are benign bone growths that can occur in individuals with Langer-Giedion syndrome. They typically form near joints. If they cause pain, limit movement, or press on nerves, they may need to be surgically removed. Regular monitoring by an orthopaedic specialist is often recommended.
What kind of support is available for intellectual disability in LGS?
Individuals with Langer-Giedion syndrome who experience intellectual disability can benefit from various forms of support. This may include special educational needs programmes, speech and language therapy, occupational therapy, and physiotherapy. The specific support depends on the individual's needs and is generally accessed through NHS services.
How is Langer-Giedion syndrome diagnosed?
Diagnosis of Langer-Giedion syndrome is confirmed through genetic testing, usually a chromosomal microarray (CMA), which can detect the specific microdeletion on chromosome 8. Clinical suspicion based on characteristic features, such as facial appearance and skeletal changes, often leads to referral for genetic testing.
Are there other names for Langer-Giedion syndrome?
Yes, Langer-Giedion syndrome is also known as trichorhinophalangeal syndrome type II (TRPS II) or 8q24.11-q24.13 deletion syndrome. These names refer to aspects of the condition's features or its genetic cause.
References
- Adam MP, Bick S, Mirzaa GM. Trichorhinophalangeal Syndrome. 1993. PMID: 28426188
- Devidayal, Marwaha RK. Langer-Giedion Syndrome. Indian pediatrics. 2006. PMID: 16528117
- Hall BD, Langer LO, Giedion A. Langer-Giedion syndrome. Birth defects original article series. 1974. PMID: 4549298
- George R, Najmuddin F, Rai R. Langer-giedion syndrome: a distinct phenotype. Iranian journal of pediatrics. 2014. PMID: 25793078
- Shin HT, Chang MW. Trichorhinophalangeal syndrome, type II (Langer-Giedion syndrome). Dermatology online journal. 2001. PMID: 12165224
- Dallapiccola B, Mingarelli R, Novelli G. The link between cytogenetics and mendelism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1995. PMID: 7605907
- Vaidya VU, Parikh AP, Bharucha BA. Langer Giedion syndrome. Indian pediatrics. 1988. PMID: 3265410
- Katge FA, Rusawat BD, Shivasharan PR. Langer-Giedion Syndrome: a Rare Case Report. Journal of dentistry (Shiraz, Iran). 2016. PMID: 27602401